Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
2.390
+0.180 (8.14%)
At close: Feb 6, 2026, 4:00 PM EST
2.386
-0.004 (-0.16%)
After-hours: Feb 6, 2026, 7:19 PM EST
Zentalis Pharmaceuticals Revenue
Zentalis Pharmaceuticals had revenue of $26.87M in the twelve months ending September 30, 2025, down -33.76% year-over-year. In the year 2024, Zentalis Pharmaceuticals had annual revenue of $67.43M.
Revenue (ttm)
$26.87M
Revenue Growth
-33.76%
P/S Ratio
6.38
Revenue / Employee
$161,837
Employees
166
Market Cap
154.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 67.43M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Century Therapeutics | 113.34M |
| ProQR Therapeutics | 18.86M |
| Caribou Biosciences | 9.30M |
| Compugen | 6.90M |
| Cibus | 3.79M |
| Rani Therapeutics Holdings | 1.20M |
ZNTL News
- 3 days ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference - GlobeNewsWire
- 4 weeks ago - Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 - GlobeNewsWire
- 2 months ago - Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market - Seeking Alpha
- 3 months ago - Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress - GlobeNewsWire
- 3 months ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 5 months ago - Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha